Today's Rundown Featured Story | | | Tuesday, March 6, 2018 We started the Rotten Tomatoes special feature last year to spotlight companies that haven't followed through on the tough ethical and scientific demands of the biotech industry. This year, we’re at it again with a bit of a twist: We included companies bruised in 2016 but revived in 2017. |
|
|
Top Stories Tuesday, March 6, 2018 Autolus files for a Nasdaq IPO after kicking off three phase 1/2 trials of its CAR-Ts and bringing its private financing haul up to $173 million. Tuesday, March 6, 2018 Magenta could pay the German biotech up to $334 million in milestones if the antibody drug conjugate pacts hit their targets. Tuesday, March 6, 2018 The CEO of cell therapy startup Adicet Bio has retired, leaving an interim leader in charge while the board searches for a permanent replacement. Aya Jakobovits, Ph.D., is retaining her seat on the board and will serve as a senior strategic adviser but is no longer president and CEO of the company she founded with OrbiMed in 2014. Tuesday, March 6, 2018 Caladrius is boosting its pipeline with a late-stage cell therapy for refractory angina. Monday, March 5, 2018 Josef von Rickenbach, the chairman and CEO of Parexel, will retire from his daily CEO duties at the CRO after a 35-year tenure, passing the baton to Jamie Macdonald, who was previously the helmsman of INC Research. | This week's sponsor is cobra:bio. | |  | 1ml Long Syringe Line Now Available
In response to customer demand, Cobra has invested in an expansion of capabilities for batches up to 20k units. Today ~80% of the market for high value, low volume biologicals utilises the 1ml long format. More... |
Resources Sponsored by: MK&A There’s no magic bullet to successful access but insights from patient advocates and industry experts can help shape future strategies. Learn how in this webinar. Sign up now! Sponsored by: Reprints Desk The competitive landscape in medical device R&D is tough. And simply investing in R&D is no guarantee for profitability. So how do you accelerate time-to-market? Presented by: Box and USDM Life Sciences Learn how biopharma and medical device companies can now collaborate on, manage and distribute regulated clinical, lab and manufacturing content in Box. That means all of your content is standardized on a single content repository that meets regulatory and compliance standards, so you can eliminate inefficient silos, enable seamless collaboration and accelerate the validation process. Sponsored by: RBC Wealth Management Employee stock option trading & administration, Restricted stock transactions (Rule 144), Affiliated trading plans (10b5-1), Directed share plans, Equity comp plan administration — private to public Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Presented by: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Presented by: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented by: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented by: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented by: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored by: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. | 
